1-{6-[((3R)-oxolan-3-yl)amino]-9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl}pyrazole-4-carboxylic acid | 915097-55-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 1-{6-[((3R)-oxolan-3-yl)amino]-9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl}pyrazole-4-carboxylic acid
• 英文别名: 1-[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-[[(3R)-oxolan-3-yl]amino]purin-2-yl]pyrazole-4-carboxylic acid
• CAS: 915097-55-1
• 化学式: C₁₈H₂₁N₇O₇
• 分子量: 447.407
• InChiKey: KCXUOHHIHWDYEB-ZGOQAQPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  190
• 氢给体数：
  5
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  1-{6-[((3R)-oxolan-3-yl)amino]-9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl}pyrazole-4-carboxylic acid 、 苄胺 在 4-二甲氨基吡啶 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (1-{6-[((3R)-oxolan-3-yl)amino]-9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl}pyrazol-4-yl)-N-benzylcarboxamide
  参考文献：
  名称：

  WO2006/125211

  摘要：

  公开号：
• 作为产物：
  描述：

  (2R,3R,4R,5R)-4-(acetyloxy)-2-[(acetyloxy)methyl]-5-(2,6-dichloro-9H-purin-9-yl)tetrahydro-3-furanyl acetate 在 sodium hydroxide 、 三乙胺 、 肼 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 1-{6-[((3R)-oxolan-3-yl)amino]-9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl}pyrazole-4-carboxylic acid
  参考文献：
  名称：

  N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists

  摘要：

  A series of new selective, high affinity A(1)-AdoR agonists is reported. Compound 23 that incorporated a carboxylic acid functionality in the 4-position of the pyrazole ring displayed K-iL value of 1 nM for the A(1)-AdoR and > 5000-fold selectivity over the A(3) and A(2A)-AdoRs. In addition, compound 19 that incorporated a carboxamide functionality in the 4-position of the pyrazole ring displayed subnanomolar affinity for the A(1)-AdoR (K-iL = 0.6 nM) and > 600-fold selectivity over the A(3) and A(2A)-AdoRs. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.065

文献信息

• A1 adenosine receptor agonists
  申请人：Elzein Elfatih

  公开号：US20060281705A1

  公开（公告）日：2006-12-14

  Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.

  本发明涉及一种新型化合物，其为部分和完全A1腺苷受体激动剂，具有以下结构（公式I）： 该化合物可用于治疗各种疾病状态，特别是心动过速和房颤、心绞痛和心肌梗死。
• A1 ADENOSINE RECEPTOR AGONISTS
  申请人：Elzein Elfatih

  公开号：US20090156544A1

  公开（公告）日：2009-06-18

  Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.

  本发明涉及一种新型化合物，其为部分和完全A1腺苷受体激动剂，具有公式I的结构，可用于治疗各种疾病状态，特别是心动过速和心房颤动、心绞痛和心肌梗死。
• US7514417B2
  申请人：——

  公开号：US7514417B2

  公开（公告）日：2009-04-07
• [EN] A1 ADENOSINE RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RECEPTEURS DE L'ADENOSINE A1
  申请人：CV THERAPEUTICS INC

  公开号：WO2006125211A1

  公开（公告）日：2006-11-23

  [EN] Disclosed are novel compounds that are partial and full A₁ adenosine receptor agonists having the structure of Formula (I): which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
  [FR] L'invention concerne des composés qui sont des agonistes partiels et complets des récepteurs de l'adénosine A₁ présentant la structure de formula (I): lesquels sont utiles dans le traitement de divers états de maladies, notamment la tachycardie, le flutter auriculaire, l'angine et l'infarctus du myocarde.